Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback